Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02688556 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca
A Phase 3 study, sponsored by Sun Pharmaceutical Industries Limited.
- Completed
- Registry status
- Phase 3
- Development phase
- 745
- Enrollment target
NCT02688556 is a Phase 3 study that has completed, run by Sun Pharmaceutical Industries Limited. The registered enrollment target is 745 participants.
The verdict
NCT02688556, a Phase 3 study, has completed, sponsored by Sun Pharmaceutical Industries Limited.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 745 participants
- Enrollment target
Study Summary
This is a randomized, double-masked, vehicle-controlled study of the safety and efficacy of OTX-101 (0.09% cyclosporine nanomicellar solution) in the treatment of keratoconjunctivitis sicca to be conducted at approximately 50 sites.
Interventions
- DRUG cyclosporine
- DRUG vehicle of OTX-101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 745 participants |
| Start Date | 2016-02 |
| Est. Completion | 2016-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02688556
The ClinicalTrials.gov registry entry for NCT02688556 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 745 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sun Pharmaceutical Industries Limited, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which cyclosporine is the first listed.
NCT02688556 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02688556 about?
NCT02688556 is a clinical study titled "Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca". This is a randomized, double-masked, vehicle-controlled study of the safety and efficacy of OTX-101 (0.09% cyclosporine nanomicellar solution) in the treatment of keratoconjunctivitis sicca to be conducted at approximately 50 sites.
What is the current status of trial NCT02688556?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 745 participants. The study started on 2016-02. Estimated completion is 2016-12.
What interventions are being tested in trial NCT02688556?
The interventions under investigation include: cyclosporine (DRUG), vehicle of OTX-101 (DRUG).
Who is sponsoring clinical trial NCT02688556?
This trial is sponsored by Sun Pharmaceutical Industries Limited, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.